Literature DB >> 22154684

Short echo time in vivo prostate ¹H-MRSI.

Niranjan Venugopal1, Boyd McCurdy, Salem Al Mehairi, Aziz Alamri, Gurdarshan S Sandhu, Sri Sivalingam, Darrel Drachenberg, Lawrence Ryner.   

Abstract

Visualization of short echo time (TE) metabolites in prostate magnetic resonance spectroscopic imaging is difficult due to lipid contamination and pulse timing constraints. In this work, we present a modified pulse sequence to permit short echo time (TE=40ms) acquisitions with reduced lipid contamination for the detection of short TE metabolites. The modified pulse sequence employs the conformal voxel MRS (CV-MRS) technique, which automatically optimizes the placement of spatial saturation planes to adapt the excitation volume to the shape of the prostate, thus reducing lipid contamination in prostate magnetic resonance spectroscopic imaging (MRSI). Metabolites were measured and assessed using a modified version of LCModel for analysis of in vivo prostate spectra. We demonstrate the feasibility of acquiring high quality spectra at short TEs, and show the measurement of short TE metabolites, myo-inositol, scyllo-inositol, taurine and glutamine/glutamate for both single and multi-voxel acquisitions. In single voxels experiments, the reduction in TE resulted in 57% improvement in the signal-to-noise ratio (SNR). Additional 3D MRSI experiments comparing short (TE=40 ms), and long (TE=130 ms) TE acquisitions revealed a 35% improvement in the number of adequately fitted metabolite peaks (775 voxels over all subjects). This resulted in a 42 ± 24% relative improvement in the number of voxels with detectable citrate that were well-fitted using LCmodel. In this study, we demonstrate that high quality prostate spectra can be obtained by reducing the TE to 40 ms to detect short T2 metabolites, while maintaining positive signal intensity of the spin-coupled citrate multiplet and managing lipid suppression.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22154684     DOI: 10.1016/j.mri.2011.09.020

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  5 in total

Review 1.  Metabolic Imaging in Humans.

Authors:  Taylor L Fuss; Leo L Cheng
Journal:  Top Magn Reson Imaging       Date:  2016-10

Review 2.  Developments in proton MR spectroscopic imaging of prostate cancer.

Authors:  Angeliki Stamatelatou; Tom W J Scheenen; Arend Heerschap
Journal:  MAGMA       Date:  2022-04-20       Impact factor: 2.533

3.  The effect of antitumor glycosides on glioma cells and tissues as studied by proton HR-MAS NMR spectroscopy.

Authors:  Isabel García-Álvarez; Leoncio Garrido; Lorenzo Romero-Ramírez; Manuel Nieto-Sampedro; Alfonso Fernández-Mayoralas; Ramón Campos-Olivas
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

4.  Evaluation of short-TE (1)H MRSI for quantification of metabolites in the prostate.

Authors:  Meer Basharat; Maysam Jafar; Nandita M deSouza; Geoffrey S Payne
Journal:  NMR Biomed       Date:  2014-02-12       Impact factor: 4.044

5.  TE = 32 ms vs TE = 100 ms echo-time (1)H-magnetic resonance spectroscopy in prostate cancer: Tumor metabolite depiction and absolute concentrations in tumors and adjacent tissues.

Authors:  Meer Basharat; Geoffrey S Payne; Veronica A Morgan; Chris Parker; David Dearnaley; Nandita M deSouza
Journal:  J Magn Reson Imaging       Date:  2015-08-10       Impact factor: 4.813

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.